Literature DB >> 23873771

iBAT on bone.

Yihong Wan1.   

Abstract

Mesh：

Year:  2013        PMID： 23873771      PMCID： PMC3713222          DOI： 10.1210/en.2013-1514

Source DB:  PubMed          Journal:  Endocrinology        ISSN： 0013-7227            Impact factor:   4.736


× No keyword cloud information.
  18 in total

1.  PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors.

Authors:  Toru Akune; Shinsuke Ohba; Satoru Kamekura; Masayuki Yamaguchi; Ung-Il Chung; Naoto Kubota; Yasuo Terauchi; Yoshifumi Harada; Yoshiaki Azuma; Kozo Nakamura; Takashi Kadowaki; Hiroshi Kawaguchi
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

2.  Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ.

Authors:  Wei Wei; Paul A Dutchak; Xunde Wang; Xunshan Ding; Xueqian Wang; Angie L Bookout; Regina Goetz; Moosa Mohammadi; Robert D Gerard; Paul C Dechow; David J Mangelsdorf; Steven A Kliewer; Yihong Wan
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-06       Impact factor: 11.205

3.  Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

Authors:  Steven E Kahn; Steven M Haffner; Mark A Heise; William H Herman; Rury R Holman; Nigel P Jones; Barbara G Kravitz; John M Lachin; M Colleen O'Neill; Bernard Zinman; Giancarlo Viberti
Journal:  N Engl J Med       Date:  2006-12-04       Impact factor: 91.245

4.  A circadian-regulated gene, Nocturnin, promotes adipogenesis by stimulating PPAR-gamma nuclear translocation.

Authors:  Masanobu Kawai; Carla B Green; Beata Lecka-Czernik; Nicholas Douris; Misty R Gilbert; Shihoko Kojima; Cheryl Ackert-Bicknell; Neha Garg; Mark C Horowitz; Martin L Adamo; David R Clemmons; Clifford J Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-24       Impact factor: 11.205

5.  Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation.

Authors:  Beata Lecka-Czernik; Elena J Moerman; David F Grant; Jürgen M Lehmann; Stavros C Manolagas; Robert L Jilka
Journal:  Endocrinology       Date:  2002-06       Impact factor: 4.736

Review 6.  Thiazolidinedione-induced skeletal fragility--mechanisms and implications.

Authors:  Andrew Grey
Journal:  Diabetes Obes Metab       Date:  2008-07-29       Impact factor: 6.577

7.  Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes.

Authors:  Bernard Zinman; Steven M Haffner; William H Herman; Rury R Holman; John M Lachin; Barbara G Kravitz; Gitanjali Paul; Nigel P Jones; R Paul Aftring; Giancarlo Viberti; Steven E Kahn
Journal:  J Clin Endocrinol Metab       Date:  2009-10-29       Impact factor: 5.958

8.  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Authors:  Philip D Home; Stuart J Pocock; Henning Beck-Nielsen; Paula S Curtis; Ramon Gomis; Markolf Hanefeld; Nigel P Jones; Michel Komajda; John J V McMurray
Journal:  Lancet       Date:  2009-06-06       Impact factor: 79.321

9.  Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

Authors:  Steven E Kahn; Bernard Zinman; John M Lachin; Steven M Haffner; William H Herman; Rury R Holman; Barbara G Kravitz; Dahong Yu; Mark A Heise; R Paul Aftring; Giancarlo Viberti
Journal:  Diabetes Care       Date:  2008-01-25       Impact factor: 19.112

10.  PPAR-gamma regulates osteoclastogenesis in mice.

Authors:  Yihong Wan; Ling-Wa Chong; Ronald M Evans
Journal:  Nat Med       Date:  2007-12-02       Impact factor: 53.440
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.